Vitamin A: more than a renewal booster

Retinoids — vitamin A derivatives, most notably all-trans retinoic acid (ATRA) — rank among the best-studied and most clinically validated actives in dermatology. Decades of research have confirmed their ability to reduce signs of photoaging, promote epidermal renewal, and stimulate collagen synthesis. The conventional explanation for how they work has always been straightforward: retinoids drive basal keratinocyte proliferation, and the epidermis renews itself faster as a result. That explanation was convenient — but, as it turns out, incomplete.

A new study proposes a fundamentally different picture. Rather than simply pushing cells to divide faster, ATRA acts as a fine-tuned regulator of epidermal stem cell heterogeneity — governing cell fate and shaping the functional identity of distinct stem cell populations [1].

Two stem cell pools and the study's rationale

Normal epidermal homeostasis depends on the heterogeneity of the basal layer. Mouse tail skin — a well-established experimental model — harbors two morphologically and functionally distinct epidermal stem cell populations: slow-cycling cells (marked by Dlx1/K10/ASS1) and fast-cycling cells (marked by Slc1a3/K36/SLC1A3). The slow-cycling pool sustains the long-term tissue reserve; the fast-cycling pool drives active day-to-day renewal. The interplay between these two populations maintains the balance between proliferation and differentiation in the skin [2, 3].

The authors of this study, published in the Journal of Investigative Dermatology (2026), set out to examine precisely how ATRA affects the behavior and relative proportions of these populations. Notably, the broader phenomenon — a reduction in fast-cycling epidermal zones in mouse tail skin following vitamin A treatment — was first documented as far back as 1987. Yet what actually happens at the level of individual stem cells had remained largely unexplored until now [1].

Study design: three levels of analysis

The study combined three complementary approaches. First, ATRA was applied topically to mouse tail skin, followed by histological and immunofluorescence analysis of changes in cell population composition. Second, lineage tracing was performed using transgenic mouse lines — Dlx1-CreER (for slow-cycling cells) and Slc1a3-CreER (for fast-cycling cells) — making it possible to track not just population composition at a given time point, but the fate of individual cells and their progeny over time. Third, experiments on primary human keratinocytes in vitro were conducted to determine whether the observed patterns hold in human cells. An additional dietary vitamin A deficiency mouse model was developed to assess the consequences of chronic insufficiency.

Results: redistribution, not acceleration

The central finding is this: ATRA does not simply stimulate proliferation — it systematically shifts the balance between stem cell pools. Under ATRA treatment, epidermal hyperplasia was observed; yet the proportion of fast-cycling cells (K36+) decreased significantly, while the slow-cycling pool (K10+) expanded. Importantly, ATRA enhanced proliferation in both populations — but simultaneously pushed both toward differentiation rather than self-renewal.

Lineage tracing revealed an even subtler effect: the remaining fast-cycling stem cells (Slc1a3-CreER+) in the basal layer switched to a slow-cycling developmental trajectory (K10+ lineage). In other words, ATRA does not merely alter the pace of cell division — it reprograms cellular identity itself [1].

Critically, all of these changes proved reversible: once ATRA was withdrawn, the population balance was restored. This points to an adaptive, compensatory nature of the observed shifts — the stem cell regulatory system responds to the retinoid signal, reorganizes, and then returns to its baseline state.

Experiments on primary human keratinocytes supported the relevance of these findings beyond the mouse model: ATRA increased expression of the slow-cycling cell marker (ASS1) and decreased expression of the fast-cycling marker (SLC1A3), suggesting that the identified mechanism is not model-specific and is likely operative in human skin.

The dietary vitamin A deficiency model did not produce significant changes in stem cell pool ratios under baseline conditions. The authors suggest that the impact of vitamin A deficiency on stem cell behavior may become apparent primarily under conditions of skin injury or stress.

Safety and the question of dosage

ATRA is a potent bioactive agent with pronounced dose-dependent effects. The paper explicitly notes that high retinoid concentrations are associated with retinoid dermatitis — an inflammatory response characterized by redness, peeling, and impaired skin barrier function [1]. The fact that ATRA simultaneously enhances proliferation and drives cells toward differentiation means that uncontrolled use or excessively high concentrations can disrupt the regulatory balance. Adhering to recommended concentrations and treatment regimens is not merely a precaution — it is a prerequisite for retinoid signaling to function as a regulator rather than a damaging stimulus.

Limitations

The authors are candid about the boundaries of their work. The molecular mechanism by which ATRA switches fast-cycling stem cells to a slow-cycling trajectory remains unresolved and warrants dedicated investigation. Additionally, findings from the mouse model cannot be directly extrapolated to clinical practice without further studies in human skin. Finally, the question of how vitamin A deficiency affects stem cell behavior under conditions of inflammation, injury, or chronic stress was not addressed in this study.

Clinical relevance

These findings shift the lens through which retinoid action in the skin is understood. They confirm that ATRA's effects extend well beyond cell cycle acceleration: retinoic acid regulates tissue homeostasis by fine-tuning the balance between stem cell populations with distinct functional roles [4, 5]. For skincare specialists, this means that the clinical efficacy of retinoids is not governed by a "more is better" principle, but by a precise equilibrium between proliferation and differentiation — making concentration, treatment duration, and combination with other actives genuinely consequential decisions. The reversibility of the observed changes further underscores the importance of consistent, sustained retinoid therapy rather than intermittent use.

Conclusion

This study makes a meaningful contribution to our understanding of retinoid biology at the cellular level. Retinoic acid emerges as a fundamental regulator of epidermal stem cell heterogeneity: it redistributes cell pools, shifts the balance toward differentiation, and reversibly reprograms the identity of fast-cycling cells. These effects likely underlie the well-established clinical properties of retinoids — improved barrier function, changes in skin texture, and accelerated renewal. The fact that comparable changes were reproduced in human keratinocytes points to the clinical significance of this mechanism. Future research aimed at decoding the molecular pathways governing cell fate decisions under retinoic acid signaling may reveal new therapeutic targets for skin disease and enable the development of more precise, better-tolerated retinoid regimens.

References

1. Dumrongphuttidecha T., Ishikawa M., Cabezas-Wallscheid N., Sada A. Retinoic acid signaling alters the balance of epidermal stem cell populations in the skin. J Invest Dermatol 2026; 146(5): 1332–1343.
2. Tierney M.T., Polak L., Yang Y. et al. Vitamin A resolves lineage plasticity to orchestrate stem cell lineage choices. Science 2024; 383(6687): eadi7342.
3. Cockburn K., Annusver K., Gonzalez D.G. et al. Gradual differentiation uncoupled from cell cycle exit generates heterogeneity in the epidermal stem cell layer. Nat Cell Biol 2022; 24(12) 1692–700.
4. Mascré G., Dekoninck S., Drugat B. et al. Distinct contribution of stem and progenitor cells to epidermal maintenance. Nature 2012; 489(7415): 257–62.
5. Szymański L., Skopek R., Palusińska M. et al. Retinoic acid and its derivatives in skin. Cells 2020; 9(12): 2660.